-
Product Insights
Pyelonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Pyelonephritis pipeline market research report provides comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects.
-
Sector Analysis
Gastric and Gastroesophageal Junction Adenocarcinoma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
The Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC) market size across the 8MM was valued at $1.12 billion in 2019 and is forecast to grow at a CAGR of more than 15% during 2019-2029. Growth of the market will be driven by the recent expansions of Opdivo and Keytruda into the first-line metastatic setting, further expansions for multiple agents across the 8MM, and the launches of nine pipeline agents.
-
Sector Analysis
Rheumatoid Arthritis – Global Drug Forecast and Market Analysis to 2029
The rheumatoid arthritis (RA) market is expected to grow from $26.2bn in 2019 to $29.1bn in 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 1.0%. This report discusses that although the RA market is expected to grow during the forecast period, this growth will be stymied by erosion from biosimilars. Rose Joachim, PhD, Senior Immunology Analyst at GlobalData, explains: “Between 2019 and 2029, there will be modest growth in the RA market. Growth will...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for December 2019 in Pharmaceuticals
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for December 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2019. The report portrays detailed comparative data on the number of deals and their value in the last...
-
Sector Analysis
Rheumatoid Arthritis – Global Drug Forecast and Market Analysis to 2027
Rheumatoid arthritis (RA) is an autoimmune disease that, due to a complex interplay of environmental, immunological, and genetic factors, causes chronic inflammation and progressive deformity of the joints over time. In 2017, the diagnosed prevalence of RA in the 8MM averaged 0.66% in adults 18 years of age and older and 2.7% in adults aged 60 and older. Early RA typically presents as a bilateral inflammatory joint condition, usually beginning in the smaller joints such as the fingers and toes...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.